Skip to main content
SpringerLink
Log in

Treatment of myeloma patients with renal impairment

  • short review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Abstract

Renal impairment is a common phenomenon in myeloma patients. Pathogenesis is mainly based on the presence of monoclonal paraprotein but may include myeloma-independent mechanisms as well. There are various forms of paraprotein-related renal impairment. The majority of severe cases are due to cast nephropathy where precipitation on the basis of monoclonal free light chains causes complex tubular damage. Cast nephropathy requires quick diagnosis and specific treatment. Renal impairment increases mortality in myeloma patients. A quick and sustained response to treatment is crucial for preventing long-term dialysis dependence. Apart from preventing or treating other conditions endangering kidney function, an effective antimyeloma treatment is the mainstay of therapy. Available data are limited but novel substances added considerable efficacy to preexisting treatment concepts. Bortezomib gained importance due to its rapid action and missing nephrotoxicity, but also immunmodulatory substances such as lenalidomide were shown to restore kidney function. Cytostatic substances such as cyclophosphamide, bendamustine, and doxorubicin remain valuable combination partners for novel substances in order to achieve significant tumor responses. Extracorporeal removal of free light chains by plasmapheresis or extended daily high cut-off hemodialysis, if available, may further optimize management of acute myeloma-related renal failure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

CN:

cast nephropathy

FLC:

free light chains

References

  1. Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol. 2000;65:175–81.

    Article  CAS  PubMed  Google Scholar 

  2. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson DR, Plevak ME, Therneau TM, Greipp PR. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21–33.

    Article  PubMed  Google Scholar 

  3. Blade J, Fernandez-Llama P, Bosch F, Montoliu J, Lens XM, Montoto S, Cases A, Darnell A, Rozman C, Montserrat E. Renal failure in multiple myeloma: presenting features and pictors of outcome in 94 patients from a single institution. Arch Intern Med. 1998;158:1889–93.

    Article  CAS  PubMed  Google Scholar 

  4. Murphy PT, Baldeo C, O’Kelly P, Sargant J, Thornton P, McCloy M, Conlon P, Magee C, Denton M, Quinn J. Dialysis-dependent renal failure at diagnosis continues to be associated with very poor outcome in multiple myeloma. Br J Haematol. 2014;165:890–1.

    Article  PubMed  Google Scholar 

  5. Korzets A, Tam F, Russell G, Feehally J, Walls J. The role of continuous ambulatory peritoneal dialysis in end-stage renal failure due to multiple myeloma. Am J Kidney Dis. 1990;16:216–23.

    Article  CAS  PubMed  Google Scholar 

  6. Alexanian R, Barlogie B, Dixon D. Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Intern Med. 1990;150:1693–5.

    Article  CAS  PubMed  Google Scholar 

  7. Heher EC, Rennke HG, Laubach JP, Richardson PG. Kidney disease and multiple myeloma. Clin J Am Soc Nephrol. 2013;8:2007–17.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Zucchelli P, Pasquali S, Cagnoli L, Ferrari G. Controlled plasma exchange trial in acute renal failure due to multiple myeloma. Kidney Int. 1988;33:1175–80.

    Article  CAS  PubMed  Google Scholar 

  9. Johnson WJ, Kyle RA, Pineda AA, O’Brien PC, Holley KE. Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy. Arch Intern Med. 1990;150:863–9.

    Article  CAS  PubMed  Google Scholar 

  10. Clark WF, Stewart AK, Rock GA, Sternbach M, Sutton DM, Barrett BJ, Heidenheim AP, Garg AX, Churchill DN. Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med. 2005;143:777–84.

    Article  PubMed  Google Scholar 

  11. Burnette BL, Leung N, Rajkumar SV. Renal improvement in myeloma with bortezomib plus plasma exchange. N Engl J Med. 2011;364:2365–6.

    Article  CAS  PubMed  Google Scholar 

  12. Heyne N, Denecke B, Guthoff M, Oehrlein K, Kanz L, Haring HU, Weisel KC. Extracorporeal light chain elimination: high cut-off (HCO) hemodialysis parallel to chemotherapy allows for a high proportion of renal recovery in multiple myeloma patients with dialysis-dependent acute kidney injury. Ann Hematol. 2012;91:729–35.

    Article  CAS  PubMed  Google Scholar 

  13. Hutchison CA, Bradwell AR, Cook M, Basnayake K, Basu S, Harding S, Hattersley J, Evans ND, Chappel MJ, Sampson P, Foggensteiner L, Adu D, Cockwell P. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol. 2009;4:745–54.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Nayak L, Lazarus HM. Renal allografts in plasma cell myeloma hematopoietic cell graft recipients: on the verge of an explosion? Bone Marrow Transplant. 2013;48:338–45.

    Article  CAS  PubMed  Google Scholar 

  15. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516–20.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Chanan-Khan AA, Kaufman JL, Mehta J, Richardson PG, Miller KC, Lonial S, Munshi NC, Schlossman R, Tariman J, Singhal S. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood. 2007;109:2604–6.

    Article  CAS  PubMed  Google Scholar 

  17. Ludwig H, Adam Z, Hajek R, Greil R, Tothova E, Keil F, Autzinger EM, Thaler J, Gisslinger H, Lang A, Egyed M, Womastek I, Zojer N. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. J Clin Oncol. 2010;28:4635–41.

    Article  CAS  PubMed  Google Scholar 

  18. Ludwig H, Drach J, Graf H, Lang A, Meran JG. Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma. Haematologica. 2007;92:1411–4.

    Article  CAS  PubMed  Google Scholar 

  19. Dimopoulos MA, Richardson PG, Schlag R, Khuageva NK, Shpilberg O, Kastritis E, Kropff M, Petrucci MT, Delforge M, Alexeeva J, Schots R, Masszi T, Mateos MV, Deraedt W, Liu K, Cakana A, van de Velde H, San Miguel JF. VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. J Clin Oncol. 2009;27:6086–93.

    Article  CAS  PubMed  Google Scholar 

  20. Badros AZ, Vij R, Martin T, Zonder JA, Kunkel L, Wang Z, Lee S, Wong AF, Niesvizky R. Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety. Leukemia. 2013;27:1707–14.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Siegel D, Martin T, Nooka A, Harvey RD, Vij R, Niesvizky R, Badros AZ, Jagannath S, McCulloch L, Rajangam K, Lonial S. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica. 2013;98:1753–61.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Niesvizky R, Naib T, Christos PJ, Jayabalan D, Furst JR, Jalbrzikowski J, Zafar F, Mark T, Lent R, Pearse RN, Ely S, Leonard JP, Mazumdar M, Chen-Kiang S, Coleman M. Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naive patients undergoing front-line lenalidomide and dexamethasone therapy. Br J Haematol. 2007;138:640–3.

    Article  CAS  PubMed  Google Scholar 

  23. Klein U, Neben K, Hielscher T, Heiss C, Ho AD, Goldschmidt H. Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment. Ann Hematol. 2011;90:429–39.

    Article  CAS  PubMed  Google Scholar 

  24. Eriksson T, Hoglund P, Turesson I, Waage A, Don BR, Vu J, Scheffler M, Kaysen GA. Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis. J Pharm Pharmacol. 2003;55:1701–6.

    Article  CAS  PubMed  Google Scholar 

  25. Kastritis E, Anagnostopoulos A, Roussou M, Gika D, Matsouka C, Barmparousi D, Grapsa I, Psimenou E, Bamias A, Dimopoulos MA. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica. 2007;92:546–9.

    Article  CAS  PubMed  Google Scholar 

  26. Dimopoulos MA, Leleu X, Palumbo A, Moreau P, Delforge M, Cavo M, Ludwig H, Morgan GJ, Davies FE, Sonneveld P, Schey SA, Zweegman S, Hansson M, Weisel K, Mateos MV, Facon T, Miguel JF. Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. Leukemia. 2014;28:1573–85.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  27. Scheid C, Sonneveld P, Schmidt-Wolf IG, van der Holt B, el Jarari L, Bertsch U, Salwender H, Zweegman S, Blau IW, Vellenga E, Weisel K, Pfreundschuh M, Jie KS, Neben K, van de Velde H, Duehrsen U, Schaafsma MR, Lindemann W, Kersten MJ, Peter N, Hanel M, Croockewit S, Martin H, Wittebol S, Bos GM, van Marwijk-Kooy M, Wijermans P, Goldschmidt H, Lokhorst HM. Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial. Haematologica. 2014;99:148–54.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  28. Lentzsch S, O’Sullivan A, Kennedy RC, Abbas M, Dai L, Pregja SL, Burt S, Boyiadzis M, Roodman GD, Mapara MY, Agha M, Waas J, Shuai Y, Normolle D, Zonder JA. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. Blood. 2012;119:4608–13.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  29. Ponisch W, Andrea M, Wagner I, Hammerschmidt D, Kreibich U, Schwarzer A, Zehrfeld T, Schwarz M, Winkelmann C, Petros S, Bachmann A, Lindner T, Niederwieser D. Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone. J Cancer Res Clin Oncol. 2012;138:1405–12.

    Article  PubMed  Google Scholar 

  30. Ramasamy K, Hazel B, Mahmood S, Corderoy S, Schey S. Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease. Br J Haematol. 2011;155:632–4.

    Article  CAS  PubMed  Google Scholar 

  31. Costa LJ, Abbas J, Ortiz-Cruz KL, Kang Y, Stuart RK. Outcomes of patients with multiple myeloma and renal impairment treated with bortezomib, cyclophosphamide, and dexamethasone without plasma exchange. Eur J Haematol. 2012;89:432–4.

    Article  CAS  PubMed  Google Scholar 

  32. Song MK, Chung JS, Shin HJ, Moon JH, Lee JJ, Yoon SS, Kim JS, Lee JO, Do YR, Lee HS, Park EK. Cyclophosphamide-containing regimen (TCD) is superior to melphalan-containing regimen (MPT) in elderly multiple myeloma patients with renal impairment. Ann Hematol. 2012;91:889–96.

    Article  CAS  PubMed  Google Scholar 

  33. Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen HD, Yunus F, Bell R, Body J, Quebe-Fehling E, Seaman J. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol. 2001;19:558–67.

    CAS  PubMed  Google Scholar 

  34. Pecherstorfer M, Herrmann Z, Body JJ, Manegold C, Degardin M, Clemens MR, Thurlimann B, Tubiana-Hulin M, Steinhauer EU, van Eijkeren M, Huss HJ, Thiebaud D. Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. J Clin Oncol. 1996;14:268–76.

    CAS  PubMed  Google Scholar 

  35. Jackson GH. Renal safety of ibandronate. Oncologist. 2005;10(Suppl 1):14–8.

    Article  CAS  PubMed  Google Scholar 

  36. Cicci JD, Buie L, Bates J, van Deventer H. Denosumab for the management of hypercalcemia of malignancy in patients with multiple myeloma and renal dysfunction. Clin Lymphoma Myeloma Leuk. 2014;14:e207–11.

    Article  PubMed  Google Scholar 

  37. Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29:1125–32.

    Article  CAS  PubMed  Google Scholar 

  38. McDonald JS, McDonald RJ, Comin J, Williamson EE, Katzberg RW, Murad MH, Kallmes DF. Frequency of acute kidney injury following intravenous contrast medium administration: a systematic review and meta-analysis. Radiology. 2013;267:119–28.

    Article  PubMed  Google Scholar 

  39. Pahade JK, LeBedis CA, Raptopoulos VD, Avigan DE, Yam CS, Kruskal JB, Pedrosa I. Incidence of contrast-induced nephropathy in patients with multiple myeloma undergoing contrast-enhanced CT. AJR Am J Roentgenol. 2011;196:1094–101.

    Article  PubMed  Google Scholar 

  40. Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S, Niesvizky R, Giralt S, Fermand JP, Blade J, Comenzo RL, Sezer O, Palumbo A, Harousseau JL, Richardson PG, Barlogie B, Anderson KC, Sonneveld P, Tosi P, Cavo M, Rajkumar SV, Durie BG, San Miguel J. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol. 2010;28:4976–84.

    Article  PubMed  Google Scholar 

  41. Mussap M, Merlini G. Pathogenesis of renal failure in multiple myeloma: any role of contrast media? Biomed Res Int. 2014;2014:167125.

    PubMed Central  PubMed  Google Scholar 

  42. St Bernard R, Chodirker L, Masih-Khan E, Jiang H, Franke N, Kukreti V, Tiedemann R, Trudel S, Reece D, Chen CI. Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure. Bone Marrow Transplant. 2015;50:95–9.

  43. Parmar S, Kongtim P, Champlin R, Dinh Y, Elgharably Y, Wang M, Bashir Q, Shah JJ, Shah N, Popat U, Giralt SA, Orlowski RZ, Qazilbash MH. Auto-SCT improves survival in systemic light chain amyloidosis: a retrospective analysis with 14-year follow-up. Bone Marrow Transplant. 2014;49:1036–41.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine I – Hematology and Stem Cell Transplantation, Hemostasis and Medical Oncology, Elisabethinen Hospital Linz, Fadingerstrasse 1, 4020, Linz, Austria

    Daniel Lechner

Authors
  1. Daniel Lechner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel Lechner.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lechner, D. Treatment of myeloma patients with renal impairment. memo 8, 30–34 (2015). https://doi.org/10.1007/s12254-014-0193-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-014-0193-1

Keywords

Search

Navigation